Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 4 Neoplasm Metastasis 2 Melanoma 2 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Neoplasms 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Transitional Cell 1 Adenocarcinoma of the Stomach 1

Interventions

Oxaliplatin 166 Capecitabine 112 Fluorouracil 95 Docetaxel 85 Cisplatin 84 S 1 (combination) 83 Leucovorin 64 Paclitaxel 58 Irinotecan 56 pembrolizumab 36 sintilimab 34 Trastuzumab 34 apatinib 30 Bevacizumab 21 Surgical Procedures, Operative 19 Radiotherapy 19 titanium silicide 17 camrelizumab 17 Nivolumab 17 Ramucirumab 16 Drug Therapy 15 Hyperthermic Intraperitoneal Chemotherapy 14 Folfox protocol 14 Epirubicin 14 tislelizumab 13 Neoadjuvant Therapy 12 Cetuximab 12 XELOX 10 Tegafur 10 Carboplatin 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Stomach Neoplasms × tesetaxel × Clear all

NCT01573468 2012-07-24

TESEGAST

Genta Incorporated

Phase 2 Unknown

Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡